We adapted the homogeneous enzyme-multiplied immunoassay for methotrexate to the centrifugal analyzer. The sensitivity of the assay has been extended from 200 nmol/L down to 12.5 nmol/L. Several protocols may be followed, depending on whether the samples to be tested are from patients on low-or high-dose methotrexate regimens. Precision, accuracy, and sensitivity were satisfactory. Comparison with the enzymrc-inhibition method (x) gave the following least-squares regression: y = 1.002 Co., which allows the user to take initial and final absorbance readings at any time chosen. The printout shows initial and final readings, and the delta absorbance for each position. Analyses are made at 30 #{176}C. Set the filter wheel at 340 nm to read the increase in absorbance of NADH. Set the first reading at 15 s, the final at 180 s later.
(1), enzymic inhibition (2) , and "high-pressure" liquid chromatography (3) is well-established.
The lower limit of detection with any of these methods is about 0.01 ILmol/L. If the treatment of the patient is confined to administration of large doses of methotrexate, together with citrovorum factor given to diminish the toxic effects of the drug, the usual resulting plasma concentration of methotrexate will be such, after 24 to 48 h, that the EMIT assay will provide adequate sensitivity. However, if the doses of methotrexate are small, and no citrovorum factor is given concurrently (low-dose methotrexate), the plasma concentration in such patients measured after 24 to 48 h will be much lower than the usual concentration after the standard protocol of therapy. Therefore, we modified the method of assay, using EMIT reagents and the centrifugal analyzer, so that the lower limit of detectability was extended to 12.5 nmol/L.
We compared results by the proposed method with those by the enzymic-inhibition technique (2), which in turn had been compared with those by radioimmunoassay.
Materials and Methods

Apparatus
We performed the assay with a centrifugal analyzer (Aminco Rotochem ha; American
Instrument
Co., Silver Spring, The range of the standard curve will be from 12.5 nmol/L to 200 or 500 nmol/L, whichever upper limit is found to be suitable by experience.
If only this portion of the standard curve is used, the sensitivity of the dose response increases.
That is, the absorbance change for each incremental increase of concentration becomes greater, in the region of low concentrations.
When a fuller range of standards is used (up to 2.0 ILmol/L), the portion of the curve from 25 to 200 nmol/L shows somewhat less incremental response to dose than when a less extensive range is used.
Precision. Within-day precision was evaluated by analyzing four patients'
samples 20 times on a single rotor, during the same day. Results (in nmolfL) were for the lower-range curve (12.5-500 nmol/L): mean, 35 (SD, 2.5; CV, 7.1%); mean, 180 (SD, 12; CV, 6.7%); for the usual-range curve (100-2000 nmol/L): mean, 330 (SD, 21; CV, 6.36%); mean, 760 (SD 40; CV, 5.26%).
The same samples were dispensed into small aliquots and frozen at -20 #{176}C. Between-day precision was then assessed by assaying the samples on 20 separate days during a month. The results (in nmol/L) for the lower-range curve were: mean, 33 (SD, 2.8; CV, 8.48%); mean, 190 (SD, 14; CV, 7.37%). For the usual-range curve, results were: mean, 340 (SD, 23; CV, and mean 740 (SD, 43; CV, 5.8%). tested by adding methotrexate standard to sera that contained no drug, ranged from 95 to 101%. Serial dilutions of sera of high concentration showed suitable linearity down to the lowest limit of detectability (12.5 nmol/L). There is no carryover with the proposed method.
Clinical samples.
We previously reported (2) that the correlation of the enzymic-inhibition method to radioimmu- 
Discussion
The proposed adaptation of the EMIT methotrexate assay to the centrifugal analyzer provides a rapid, precise, and accurate method. The alternative protocol is more efficient when samples with low concentration must be tested (plasma con- low but in the range of 1.0-2.0 ILmol/L, the higher samples may be prediluted before the assay is performed. If the regular assay protocol is used (10-ILL sample, range of standards 100 to 2000 nmol/L), the low concentrations will not be measured accurately (<100 nmol/L). If the range of standards used is from 25-2000 nmol/L (with a 10-ILL sample size), the curve is very sensitive above 100 nmol/L but less so from 25 to 100 nmol/L. For example, the absorbance change with the full-range curve is 0.006 for concentrations from 25 to 50 nmol/L, whereas with the low-range curve the absorbance change is 0.026.
As many as 28 samples can be assayed in 3 mm. The alternative protocol allows the efficient and rapid measurement of samples obtained from patients receiving low-dose methotrexate therapy. The influence of metabolites on the assay remains undetermined. In particular, the metabolites 7-hydroxymethotrexate, 4-amino-4-deoxy-N'#{176}-methylpteroic acid, diglutamate, and triglutamate methotrexate should be examined for their effect on the assay, especially at very low concentrations of methotrexate.
Our experience has been largely the assay of samples from patients on usual or high-dose therapy, and we have found very low methotroxate concentrations in those patients after many days. This observation suggests that metabolites have no appreciable influence on the assay. However, patients receiving low-dose therapy with no concurrent citrovorum factor should be examined for metabolites to see if these influence the assay when the standard curve is deliberately set to detect very low concentrations. When methotrexate is in very high concentration, its metabolism is extensive (4); perhaps in patients on low-dose therapy, however, metabolism may not be so extensive, so that metabolites would be less likely to interfere in the assay technique.
